Balanced on the Biggest Wave: Nirsevimab for Newborns

Keyphrases

• Respiratory Syncytial Virus 100%
• Large Waves 100%
• Nirsevimab 100%
• Hospitalization 40%
• Severe Disease 40%
• Congenital Heart Disease 40%
• High-risk Infants 40%
• Virus Diseases 40%
• Palivizumab 40%
• Number-needed-to-treat 40%
• Bronchiolitis 20%
• Hospitalization Risk 20%
• United States 20%
• Virus 20%
• Comorbidity 20%
• Large Population 20%
• Healthy children 20%
• Monoclonal Antibody 20%
• Randomized Controlled Trial 20%
• Novel Therapies 20%
• Antigenic Site 20%
• Long-term Consequences 20%
• Asthma 20%
• Neutralizing Activity 20%
• Disease Prevention 20%
• Centers for Disease Control 20%
• Genetic Variability 20%
• Preterm Infants 20%
• Rash 20%
• Term Infants 20%
• Interdisciplinary Collaboration 20%
• Vaccine Development 20%
• Late Preterm Infant 20%
• Genetic Code 20%
• Chronic Lung Disease 20%
• Injection Site Reaction 20%
• Late Preterm 20%
• Language Delay 20%
• Causes of Hospitalization 20%
• Medical Attention 20%
• Infant Risk 20%
• Healthy Preterm 20%
• Up to Five 20%
• Maternal Immunity 20%
• Optimal Protection 20%
• Equitable Distribution 20%
• Neonatal Vaccines 20%
• High-risk Preterm Infants 20%
• Broad Neutralization 20%
• Monoclonal Antibody Targeting 20%
• Severe Respiratory Syncytial Virus 20%
• Prefusion protein 20%

Immunology and Microbiology

• Human Respiratory Syncytial Virus 100%
• Nirsevimab 100%
• Monoclonal Antibody 33%
• Palivizumab 33%
• Asthma 16%
• Genetic Variability 16%
• Infancy 16%
• Bronchiolitis 16%
• Morbidity 16%
• Genetic Code 16%
• Comorbidity 16%
• Virus 16%
• Lung 16%